Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis.
Giampietro A, Chiloiro S, Urbani C, Pivonello R, Carlsson MO, Dassie F, Prencipe N, Ragonese M, Gomez R, Granato S, Cannavò S, Grottoli S, Maffei P, Colao A, Bogazzi F, Bianchi A. Giampietro A, et al. Among authors: cannavo s. Endocr Connect. 2024 Jan 29;13(3):e230247. doi: 10.1530/EC-23-0247. Print 2024 Mar 1. Endocr Connect. 2024. PMID: 38197875 Free PMC article.
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, de Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E. Giustina A, et al. Among authors: cannavo s. Eur J Endocrinol. 2009 Aug;161(2):331-8. doi: 10.1530/EJE-09-0372. Epub 2009 May 22. Eur J Endocrinol. 2009. PMID: 19465485 Clinical Trial.
Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.
Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavò S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A. Mazziotti G, et al. Among authors: cannavo s. Eur J Endocrinol. 2011 Mar;164(3):341-7. doi: 10.1530/EJE-10-0811. Epub 2011 Jan 6. Eur J Endocrinol. 2011. PMID: 21212103 Clinical Trial.
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients.
Colao A, Cotta OR, Ferone D, Torre ML, Ferraù F, Di Somma C, Boschetti M, Teti C, Savanelli MC, Alibrandi A, Trimarchi F, Cannavò S. Colao A, et al. Among authors: cannavo s. Clin Endocrinol (Oxf). 2013 Aug;79(2):211-6. doi: 10.1111/cen.12122. Epub 2013 May 6. Clin Endocrinol (Oxf). 2013. PMID: 23215853
HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.
Trovato M, Torre ML, Ragonese M, Simone A, Scarfì R, Barresi V, Giuffrè G, Benvenga S, Angileri FF, Tuccari G, Trimarchi F, Ruggeri RM, Cannavò S. Trovato M, et al. Among authors: cannavo s. Endocrine. 2013 Dec;44(3):735-43. doi: 10.1007/s12020-013-9950-x. Epub 2013 Apr 11. Endocrine. 2013. PMID: 23576023
431 results